TY - JOUR T1 - Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 3781 LP - 3788 VL - 36 IS - 7 AU - SACHIKO SHIRAIWA AU - TETSUSHI KINUGASA AU - AKIHIKO KAWAHARA AU - TOMOAKI MIZOBE AU - TAKAFUMI OHCHI AU - KOTARO YUGE AU - SHINYA FUJINO AU - MITSUHIRO KATAGIRI AU - SUSUMU SHIMOMURA AU - KENSUKE TAJIRI AU - TOMOYA SUDO AU - MASAYOSHI KAGE AU - MICHIHIKO KUWANO AU - YOSHITO AKAGI Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3781.abstract N2 - Background/aim: Y-Box-binding protein-1 (YB-1), a DNA/RNA-binding protein, is an important oncogenic transcription and translation factor. We aimed to evaluate the relationships between nuclear YB-1 expression, epidermal growth factor receptor (EGFR) status, and poor clinical outcomes in patients with colorectal cancer (CRC). Materials and Methods: Nuclear YB-1 expression was immunohistochemically analyzed in CRC tissues obtained from 124 patients who underwent curative resection between 2005 and 2008. Correlations between nuclear YB-1 expression, various clinicopathological characteristics, EGFR status, and prognostic factors were evaluated. Results: High-grade nuclear YB-1 expression was detected in 62.9% of cases and was found to be an independent predictor of poorer overall survival (p<0.001) and relapse-free survival (p<0.001). A trend was also observed towards a positive correlation between nuclear YB-1 expression and EGFR status (p=0.051). Conclusion: Nuclear YB-1 expression is a useful prognostic biomarker that correlates with EGFR status in patients with CRC. ER -